

Know what's ahead

Assessing diabetes risk





First, **know the risk**, with earlier diagnostic insight

Know more across the entire **diabetes
care continuum**



With the rising rates of obesity, the need for diabetes risk identification, prevention, and management is more critical than ever.¹

Quest Diagnostics offers a comprehensive array of diabetes laboratory testing services to help you manage diabetes in all of your patients, no matter where they are on the diabetes care continuum—ensuring continuity of care.



RISK ASSESSMENT

Knowing is preventing

Identify prediabetes and high risk early and in more patients, and prevent the onset of type 2

We offer tests and risk panels that allow you to get it right sooner. Now you can identify more patients with prediabetes who are at high risk of developing diabetes. Recognizing risk earlier means you can do more to stop or delay the progression to diabetes before it becomes more complex to manage.

Our diabetes risk tests offer key advantages, so you can make a difference when it matters most:

Combined glucose and HbA1c—studies have shown that testing for both provides greater accuracy in identifying prediabetes.²⁻⁵

Framingham Diabetes Risk Score—a powerful tool that measures a patient’s risk of developing diabetes over the next 8 years.⁶

Graphical report format—an easier way to communicate risk to your patients.

Our tests for assessing risk

Test Name	Test Code	Cardio IQ® Test Code	CPT Code(s)*
Diabetes Risk Panel with Score ††	92027	92026	82947, 83036, 80061
Glucose	483	91947	82947
Hemoglobin A1c	496	91732	83036
Cholesterol, Total	334	91717	82465
HDL Cholesterol	608	91719	83718
Triglycerides	896	91718	84478
8-Year Percentage Risk Score- age§ (not an AOE), gender (not an AOE), height (ft), height (in), weight (lbs), parental history of diabetes (Y/N), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), treatment for high blood pressure (Y/N)	Calculated		Calculated
Diabetes and ASCVD Risk Panel with Scores†	92062	92063	82947, 83036, 80061
Glucose	483	91947	82947
Hemoglobin A1c	496	91732	83036
Cholesterol, Total	334	91717	82465
HDL Cholesterol	608	91719	83718
Triglycerides	896	91718	84478
10-Year ASCVD Risk Score: Risk calculations are provided at no additional cost and require the following patient information at the time of order entry: age (years), gender (M/F), race (African American), systolic blood pressure (mmHg), treatment for high blood pressure (Y/N), diabetes status (Y/N), smoking status (Y/N)	Calculated		Calculated

* The CPT codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

† Panel components may be ordered separately.

‡ Available with and without score.

§ Based on the Framingham Study. The approximate 8-Year Percentage Risk estimate is based upon the assessment of adults ages 30-79.⁷



DIFFERENTIAL DIAGNOSIS

Know the right type, right away

Make more accurate diabetes diagnoses with our differential testing options

Today, much more has been learned about diabetes, enabling the diagnosis of other types in addition to type 1 and type 2. Because treatment can differ greatly among diabetes types, making the correct diagnosis early on is crucial.

With Quest Diagnostics, it's easier to guide every patient down the right treatment path. Our tools go deeper to identify forms of diabetes that may be difficult to diagnose and that may respond to different treatments:

Type 2 diabetes in children and adolescents—rising obesity rates among young people require a new approach to diagnosis.⁸

Latent autoimmune diabetes in adults (LADA)—a type of adult-onset diabetes that can progress to insulin dependence without proper management.⁹

Our differential diagnostic tests

Test Name	Test Code	CPT Code*
Glutamic Acid Decarboxylase-65 (GAD-65) Antibody Test	34878	86341
Islet Cell Antibody Test	36741	86341
C-Peptide	372	84681
IA-2 Antibody Test	36177	86341
Zinc Transporter 8 (ZnT8) Antibody	93022	86341

* The CPT codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.



Know which path to take

With guidelines-based testing, you can make more informed decisions for treatment

At Quest Diagnostics, we understand how important monitoring is for determining the success of a therapy—and for delaying or avoiding the risk of complications. We also know that following the American Diabetes Association (ADA) recommendations is key to meeting key performance measures,^{8,10,11} and we want to make that as easy as possible for you.

Our comprehensive panels will help you stay on track with guidelines-based testing, so you and your patients can easily adhere to the recommended type and frequency of tests.

Our diabetes monitoring panels of tests

Test Name	Test Code	CPT Code(s)*
Diabetes, Newly Diagnosed and Monitoring Panel†	91712	82947, 83036, 80061, 80076, 82570, 82043, 82565
Glucose	483	82947
Hemoglobin A1c	496	83036
Lipid Panel with Reflex to Direct LDL (Total Cholesterol, HDL Cholesterol, Triglycerides, Direct LDL-Cholesterol)	14852(X), (334, 608, 896, 8293)	80061, (82465, 83718, 84478) If Triglyceride result is >400 mg/dL, Direct LDL will be performed at an additional charge (CPT Code(s):83721)
Hepatic Function Panel (Total Protein, Albumin, Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase, AST, ALT)	10256(X), (754, 223, 287, 285, 234, 822, 823)	80076, (84155, 82040, 82247, 82248, 84075, 84450, 84460)
Microalbumin, Random Urine with Creatinine	6517	82043, 82570
Creatinine, Serum	375	82565
Creatinine, Random Urine	8459	82570
Diabetes, Advancing Chronic Kidney Disease (CKD) Management Panel†	91713	80051, 82570, 82043, 82565, 85018, 83970, 82310, 84100, 82306
Electrolyte Panel (Sodium, Potassium, Chloride, Carbon dioxide)	34392(X), (836, 733, 330, 310)	80051, (82374, 82435, 84132, 84295)
Microalbumin, Random Urine with Creatinine	6517	82043, 82570
Creatinine, Serum	375	82565
Creatinine, Random Urine	8459	82570
Hemoglobin	510	85018
PTH, Intact and Calcium	8837	82310, 83970
Phosphate (as Phosphorus)	718	84100
Vitamin D, 25-Hydroxy, Total, Immunoassay	17306	82306
Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score Panel (Glucose, AST, ALT, Platelet Count, Albumin)†	91979, (483, 822, 823, 723, 223)	82947, 84450, 84460, 85049, 82040

* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

† Panel components may be ordered separately.

Help patients stay ahead, and delay or avoid complications

When it comes to diabetes, patient compliance is especially important. Improved adherence is associated with greater glycemic control, decreased hospitalization, and other clinical benefits.

We offer an array of tools to help your patients stay organized, motivated, and get their testing done on time—something now considered a priority for our healthcare system. Your patients can get ahead of diabetes with:

MyQuest™ mobile app—a convenient way for patients to view, access, and securely share health information, see test results, and monitor weight and body mass wirelessly.

TestMinder®—helps patients schedule and remember testing via email, text, or phone.

Knowing what's ahead can make all the difference.
Let us help.



Contact your Quest Diagnostics sales representative or visit [QuestDiagnostics.com/KnowDiabetes](https://www.questdiagnostics.com/KnowDiabetes).

References

1. Centers for Disease Control. Maps of diagnosed diabetes and obesity in 1994, 2000, and 2010. Available at: www.cdc.gov/diabetes/statistics/slides/maps_diabetesobesity94.pdf. Accessed October 27, 2016.
2. Schöttker B, et al. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. *Eur J Epidemiol*. 2011;26:779-787.
3. Sato KK, et al. Combined measurement of fasting plasma glucose and A1c is effective for the prediction of type 2 diabetes. The Kansai Healthcare Study. *Diabetes Care*. 2009;32:644-646.
4. Soulimane S, et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. *Diab Res Clin Pract*. 2012;96:392-399.
5. Wang W, et al. Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes. *Diabetes Care*. 2011;34:363-368.
6. Wilson PWF, et al. Prediction of incident diabetes mellitus in middle-aged adults. The Framingham Offspring Study. *Arch Intern Med*. 2007;167:1068-1074.
7. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. *Arch Intern Med*. 2007 May 28;167:1068-74.
8. Standards of Medical Care in Diabetes—2014. *Diabetes Care*. 2014;37 (suppl 1):S14-S80. Pages S42-S43.
9. Fourlanos S, et al. A clinical screening tool identifies autoimmune diabetes in adults. *Diabetes Care*. 2006;29:970-975.
10. National Committee for Quality Assurance. What is the current state of quality of care in diabetes? Available at: www.ncqa.org/PublicationsProducts/OtherProducts/QualityProfiles/FocusonDiabetes/WhatistheCurrentStateofQualityofCare.aspx. Accessed October 27, 2016.
11. Medicare.gov. Star ratings. Available at: www.medicare.gov/find-a-plan/staticpages/rating/planrating-help.aspx. Accessed October 27, 2016.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2017 Quest Diagnostics Incorporated. All rights reserved. SB3419 1/2017